Rituximab in association with rapamycin for post‐transplant lymphoproliferative disease treatment

Post‐transplant lymphoproliferative disease (PTLD) is an uncommon but life‐threatening complication of solid‐organ and blood stem‐cell transplants. It responds poorly to therapy, including reduction of immunosuppression, interferon, antivirals or chemotherapy. Small series of PTLD successfully treat...

Full description

Saved in:
Bibliographic Details
Published inTransplant international Vol. 16; no. 3; pp. 202 - 206
Main Authors Garcia, Valter Duro, Bonamigo Filho, José Luz, Neumann, Jorge, Fogliatto, Laura, Geiger, Anna Maria, Garcia, Clotilde Druck, Barros, Vivianne, Keitel, Elizete, Bittar, Antonio Eduardo, Santos, Auri Ferrera, Roithmann, Sergio
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Publishing Ltd 01.03.2003
Blackwell Publishing
Subjects
Adolescent
Antibodies, Monoclonal - therapeutic use
Antibodies, Monoclonal, Murine-Derived
Biological and medical sciences
Drug Therapy, Combination
Humans
Immunosuppressive Agents - therapeutic use
Kidney Transplantation - adverse effects
Lymphoproliferative Disorders - drug therapy
Lymphoproliferative Disorders - etiology
Male
Medical sciences
Miscellaneous
Pharmacology. Drug treatments
Post transplant lymphoproliferative disease
Rapamycin
Rituximab
Sirolimus - therapeutic use
Time Factors
Transplantation
Treatment Outcome
Human
Sirolimus
Stem cell
Homograft
Rituximab
Malignant hemopathy
Transplantation
Rapamycin
Homotransplantation
Macrolide
Blood
Case study
Chemotherapy
Treatment
Surgery
Lymphoproliferative syndrome
Post transplant lymphoproliferative disease
Complication
Graft
Immunosuppressive agent
Organ
Online AccessGet full text

Cover

More Information
Summary:Post‐transplant lymphoproliferative disease (PTLD) is an uncommon but life‐threatening complication of solid‐organ and blood stem‐cell transplants. It responds poorly to therapy, including reduction of immunosuppression, interferon, antivirals or chemotherapy. Small series of PTLD successfully treated with rituximab have been reported, and experimental studies suggest that rapamycin inhibits growth of human Epstein‐Barr virus‐transformed B lymphocytes. We report two cases of PTLD after renal transplantation that were successfully treated with rituximab in association with rapamycin. This report suggests that rituximab associated with rapamycin could be an effective and safe treatment for PTLD.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:0934-0874
1432-2277
DOI:10.1111/j.1432-2277.2003.tb00287.x